What is more, Zeng et al. [36] showed that concomitant administration of gefitinib and WBRT was found to result in higher treatment response and disease control rates in patients with EGFR-sensitive mutations and NSCLC brain metastases compared with gefitinib alone. Here, EGFR is linked to non-small cell lung carcinoma.